Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients

被引:0
|
作者
Carmina Montoliu
Blanca Piedrafita
Miguel A. Serra
Juan A. del Olmo
Antonio Ferrandez
José M. Rodrigo
Vicente Felipo
机构
[1] Universidad de Valencia,Servicio de Hepatología, Departamento de Medicina, Hospital Clínico Universitario
[2] Fundación de la Comunidad Valenciana Centro de Investigacion Principe Felipe,Laboratory of Neurobiology, Centro de Investigacion Principe Felipe
[3] Universidad de Valencia,Servicio de Anatomia Patologica, Departamento de Patología Hospital Clínico Universitario
来源
关键词
Hepatic encephalopathy; Cyclic GMP; Soluble guanylate cyclase; Critical flicker frequency; PHES; Liver cirrhosis;
D O I
暂无
中图分类号
学科分类号
摘要
Patients with liver cirrhosis with normal neurological and mental status examination may present minimal forms of hepatic encephalopathy, showing intellectual function impairment that cannot be detected through general clinical examination but can be unveiled using specific neuropsychological or neurophysiological examination. Evaluation of minimal hepatic encephalopathy (MHE) in cirrhotic patients would have prognostic value. The psychometric hepatic encephalopathy score (PHES) has been recommended as the “gold standard” in the diagnosis of MHE. Altered modulation of cyclic GMP (cGMP) levels in the brain seems to be responsible for the impairment of some types of cognitive function in liver disease. In animal models of liver disease, some of the alterations in modulation of cGMP levels in the brain are reproduced in lymphocytes. The aim of the present work was to assess whether there is a correlation between the alterations in different parameters involved in modulation of cGMP levels and the presence of MHE in patients with liver disease. We studied in 46 patients with liver cirrhosis and 26 controls the performance in the PHES battery of psychometric tests and the critical flicker frequency (CFF), the concentration of cGMP in plasma and lymphocytes, activation of guanylate cyclase by nitric oxide (NO) in lymphocytes, and several parameters likely involved in altered cGMP homeostasis in liver disease such as ammonia, NO metabolites, and atrial natriuretic peptide (ANP). Activation of guanylate cyclase by NO in lymphocytes and cGMP in plasma were higher and CFF lower in patients with MHE than in patients without MHE. Ammonia, ANP, and metabolites of NO were higher in patients than in controls but were no different in patients with or without MHE. Alteration in activation of guanylate cyclase by NO in lymphocytes correlates with PHES performance, CFF, and ammonia levels. This suggests that altered modulation of guanylate cyclase by NO in lymphocytes would reflect a parallel alteration in the brain occurring in patients with MHE that would be involved in their cognitive impairment.
引用
收藏
页码:237 / 245
页数:8
相关论文
共 50 条
  • [31] Alterations in soluble guanylate cyclase content and modulation by nitric oxide in liver disease
    Rodrigo, R
    Montoliu, C
    Chatauret, N
    Butterworth, R
    Behrends, S
    Del Olma, JA
    Serra, MA
    Rodrigo, JA
    Erceg, S
    Felipo, V
    NEUROCHEMISTRY INTERNATIONAL, 2004, 45 (06) : 947 - 953
  • [32] Identification of constitutive nitric oxide synthase and soluble guanylate cyclase in Saccharomyces cerevisiae
    Kanadia, R
    McNabb, M
    Kuo, JWN
    Baptiste, J
    FASEB JOURNAL, 1997, 11 (09): : A1053 - A1053
  • [33] DEVELOPMENT OF A NOVEL BIOLUMINESCENT ASSAY FOR NITRIC OXIDE BY USING SOLUBLE GUANYLATE CYCLASE
    Sano, Yoshihiro
    Seki, Masayuki
    Suzuki, Shigeya
    Abe, Seiji
    Ito, Katsutoshi
    Arakawa, Hidetoshi
    BIOLUMINESCENCE AND CHEMILUMINESCENCE: LIGHT EMISSION: BIOLOGY AND SCIENTIFIC APPLICATIONS, 2009, : 109 - 112
  • [34] The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase
    Benza, Raymond L.
    Gruenig, Ekkehard
    Sandner, Peter
    Stasch, Johannes -Peter
    Simonneau, Gerald
    EUROPEAN RESPIRATORY REVIEW, 2024, 33 (171):
  • [35] Is the soluble guanylate cyclase pathway the only one available for nitric oxide (NO) signaling?
    Landar, Aimee
    Darley-Usmar, Victor M.
    IUBMB LIFE, 2007, 59 (02) : 110 - 112
  • [36] Development of a novel bioluminescent assay for nitric oxide using soluble guanylate cyclase
    Sano, Y.
    Seki, M.
    Suzuki, S.
    Ito, K.
    Arakawa, H.
    LUMINESCENCE, 2008, 23 (02) : 90 - 90
  • [37] Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase
    Schmidt, PM
    Rothkegel, C
    Wunder, F
    Schröder, H
    Stasch, JP
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 513 (1-2) : 67 - 74
  • [38] Soluble guanylate cyclase and nitric oxide synthase in synaptosomal fractions of bovine retina
    Margulis, A
    Pozdnyakov, N
    Dang, L
    Sitaramayya, A
    VISUAL NEUROSCIENCE, 1998, 15 (05) : 867 - 873
  • [39] Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits
    Filippov, G
    Bloch, DB
    Bloch, KD
    CIRCULATION, 1996, 94 (08) : 3050 - 3050
  • [40] Catalytic consumption of nitric oxide by 12/15-lipoxygenase:: Inhibition of monocyte soluble guanylate cyclase activation
    Coffey, MJ
    Natarajan, R
    Chumley, PH
    Coles, B
    Thimmalapura, PR
    Nowell, M
    Kühn, H
    Lewis, MJ
    Freeman, BA
    O'Donnell, VB
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (14) : 8006 - 8011